IDIX perhaps... but pls show me where in the the last 6 months, management said a successful interaction study means an automatic move to Phase 3 with NM283...
Also the data reported was on a treatable basis as per study design protocol and the PR stated this.
I too am disappointed that IDIX moved down... and it was because of the delay.
Idenix has a lot of positives... as you know Idenix is not paying for the trials, so they must clear all development w/ Novartis.
The trial met the endpoints for which it was designed.
idenix, led my mumblemouth jp comadossi are vulture food...they have not been forthright regarding 283 for a while now...a negative indicator of what was lying under the surface of their pr's was that ever present huge short position which spoke volume for the nm283 results...nvs will get to buy them out in 2008 for a pittance...
News 
Market Data 
Discover 
